Clinical Research Directory
Browse clinical research sites, groups, and studies.
Early Commencement of Adjuvant Chemotherapy for Colon Cancer
Sponsor: Kyungpook National University Hospital
Summary
This study sets up the final study end point and three detailed goals as the following. The main objective of study: This trial is done to assess the safety and benefit of early adjuvant chemotherapy from 10 to 14 days after surgery compared with conventional commencement after 2weeks for treatment of patients with colon cancer. Detailed goal of study: The primary endpoint: This study is designed to assess whether early commencement of adjuvant chemotherapy improves the 3-year disease-free survival, overall survival and recurrence rate. The secondary endpoint: This study aims to compare short-term cumulative complications between early and conventional commencement of adjuvant chemotherapy after laparoscopic resection of colon cancer. This study will also assess the quality of life and side effects of chemotherapy.
Official title: Early Commencement of Adjuvant Chemotherapy for Stage III Colon Cancer: a Multicenter Randomized Trial
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
303
Start Date
2013-01-13
Completion Date
2026-12-28
Last Updated
2026-02-12
Healthy Volunteers
No
Conditions
Interventions
timing to initiate the adjuvant FOLFOX chemotherapy
Chemotherapy regimen: FOLFOX-6, every 2weeks, total 12 cycles treatment day1: Oxaliplatin 85mg/m2 day1: Leucovorin 200mg/m2 day1: 5-FU 400mg/m2 IV bolus and 2,400mg/m2 over 46 hours
Locations (2)
Kyungpook National University Medical center
Daegu, South Korea
Jun Seok Park
Daegu, South Korea